Inebilizumab: Difference between revisions
Content deleted Content added
No Chemspider Id for this compound |
Lncallahan (talk | contribs) m added unii |
||
| Line 26: | Line 26: | ||
| ATC_prefix = none |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 74T7185BMM |
|||
| ChemSpiderID = none |
| ChemSpiderID = none |
||
| PubChem = |
| PubChem = |
||
Revision as of 14:42, 19 March 2017
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | CD19 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6504H10080N1732O2044S44 |
| Molar mass | 147 kDa g·mol−1 |
Inebilizumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer, systemic sclerosis and multiple sclerosis.[1][2]
This drug was developed by MedImmune, LLC.
References
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |